SynthesisThe Indian journal of medical research2026
Prevalence of metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus in India: A systematic review and meta-analysis.
Synthesis in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives This systematic review seeks to assess the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus (T2DM) within the Indian population. Methods A comprehensive search of SCOPUS, Web of Science and PubMed was performed for studies published from January 2000 to March 2025, using search terms such as MASLD, T2DM, NAFLD, steatohepatitis and India. This systematic review considered eligible Indian studies that included patients (≥18 years old) with T2DM and reported the prevalence of MASLD/NAFLD. The study excluded reviews, case reports, conference abstracts, editorials, and studies that did not have full texts. Pooled MASLD prevalence determined by liver biopsy, transient elastography, ultrasound, or biochemical markers was the main result. Prevalence estimates were combined using a random-effects model, and quality was evaluated using the Joanna Briggs Institute approach. Results Across the 18 selected studies, the pooled prevalence of MASLD was estimated from 81,364 adult diabetic participants. In diabetic adults, the estimated pooled prevalence of MASLD was 56.9% [95% Confidence interval (CI), 39.1-74.8]. Among these studies, the prevalence by biochemical marker was 50.4% (95% CI 38.6 - 62.2), the prevalence by ultrasonography was 55.6% (95% CI 37.1 - 74.1), and the prevalence by Fibroscan as an imaging modality was 64.3% (95% CI 31 - 97.7). Several limitations were noted; many studies provided insufficient information regarding cohort representativeness, selection criteria for non-exposed groups, and the adequacy of follow up. Interpretation and conclusions While awareness of MASLD is increasing among diabetic populations globally, data concerning its prevalence and clinical characteristics in the Indian population-especially within regional demographics-remains limited. The variability in reported prevalence rates, ranging from 34 to 94%, among individuals with T2DM indicates a pressing need for region-specific research that considers the diverse ethnic backgrounds, diets, and lifestyles throughout India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.